Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Total Valuation
Lyra Therapeutics has a market cap or net worth of $11.51M. The enterprise value is $14.78M.
Market Cap$11.51M
Enterprise Value$14.78M
Share Statistics
Lyra Therapeutics has 1,644,454 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,644,454
Owned by Insiders3.27%
Owned by Institutions24.14%
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is -8.06 and return on invested capital (ROIC) is -166.66%.
Return on Equity (ROE)-8.06
Return on Assets (ROA)-1.41
Return on Invested Capital (ROIC)-166.66%
Return on Capital Employed (ROCE)-1.79
Revenue Per Employee51.13K
Profits Per Employee-3.11M
Employee Count30
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is ―. Lyra Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value57.96
Price to FCF―
Price to Operating Cash Flow-222.96
PEG Ratio―
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -1.43.
Revenue1.53M
Gross Profit1.53M
Operating Income-96.35M
Pretax Income-93.40M
Net Income-93.44M
EBITDA-60.26M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -43.01M and capital expenditures -13.00K, giving a free cash flow of -43.02M billion.
Operating Cash Flow-43.01M
Free Cash Flow-43.02M
Free Cash Flow per Share-26.16
Dividends & Yields
Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.46
52-Week Price Change-53.24%
50-Day Moving Average8.20
200-Day Moving Average8.75
Relative Strength Index (RSI)43.56
Average Volume (3m)21.32K
Important Dates
Lyra Therapeutics upcoming earnings date is Nov 11, 2025, After Close (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date―
Financial Position
Lyra Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 2002.34%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid 39.00K in taxes.
Income Tax39.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -11.05, with an EV/FCF ratio of -9.20.
EV to Sales434.01
EV to EBITDA-11.05
EV to Free Cash Flow-9.20
EV to Operating Cash Flow-9.51
Balance Sheet
Lyra Therapeutics has $29.78M in cash and marketable securities with $32.48M in debt, giving a net cash position of $2.69M billion.
Cash & Marketable Securities$29.78M
Total Debt$32.48M
Net Cash$2.69M
Net Cash Per Share$1.64
Tangible Book Value Per Share$0.18
Margins
Gross margin is 76.23%, with operating margin of -6280.83%, and net profit margin of -6090.94%.
Gross Margin76.23%
Operating Margin-6280.83%
Pretax Margin-6088.40%
Net Profit Margin-6090.94%
EBITDA Margin-3928.42%
EBIT Margin-3959.13%
Analyst Forecast
The average price target for Lyra Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$23.00
Price Target Upside228.57% Upside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast-57.69%
EPS Growth Forecast63.76%